Related Experiment Video
Updated: Jul 11, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
Published on: August 25, 2017
Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin
Iria Castiñeiras1, Manuel Almagro, Jesús Rodríguez-Lozano
1Department of Dermatology, Hospital Juan Canalejo, La Coruña, Spain. iria.cm@canalejo.org
Abstract:
Pegylated liposomal doxorubicin (PLD) is usually used in disseminated HIV-related Kaposi's sarcoma (KS). It is the first-line treatment or second-line therapy in patients who do not tolerate or do not respond to polychemotherapy since 1995, when it was approved by the FDA. We report two cases of disseminated classic KS not associated with immunosuppression in which HHV-8 infection was demonstrated. They showed an excellent response to PLD, with good tolerance and an absence of side effects.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers